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Gastric cancer is the second cause of cancer-related deaths worldwide. Helicobacter pylori is the major risk factor for gastric cancer.
As for any type of cancer, T cells are crucial for recognition and elimination of gastric tumor cells. Unfortunately T cells, instead of
protecting from the onset of cancer, can contribute to oncogenesis. Herein we review the diﬀerent types, “friend or foe”, of T-cell
response in gastric cancer.
1.Introduction
Gastric cancer (GC) is the second cause of cancer worldwide
for cancer-related deaths [1]. The regional variations mainly
reﬂect diﬀerences in the prevalence of Helicobacter pylori
infection, which accounts for more than 60% of GC
worldwide [2].
Helicobacter pylori infection is very common in human
populations but only 1% of infected individuals develop
gastric cancer in response to persistent infection [2–4].
Certainly Helicobacter pylori plays a crucial role [3–5],
but also host factors are relevant for the outcome of the
infection [6, 7]: actually, many studies showed that the
subset of patients who progress to gastric cancer appear
to have an increased incidence of some polymorphisms in
proinﬂammatory cytokines and particularly IL-1β.
The response of the body to a cancer is not a unique
mechanismbuthasmanysimilaritieswithinﬂammationand
wound healing. The last century Virchow’s [8]o b s e r v a t i o n
of a close association between cancer and inﬂammation
anticipated the current interest in the role of immunity in
tumor pathogenesis.
Recent insights into the dynamics of the tumor microen-
vironment have begun to clarify the mechanisms underlying
tumor-promoting inﬂammation, which bears striking sim-
ilarities to wounds that fail to heal [9, 10]. Approximately
20% of cancer deaths worldwide are currently linked to
unresolved infection or inﬂammation, with gastrointestinal
malignancies representing a signiﬁcant proportion of this
disease burden: the most frequent associations are gastric
carcinoma and Helicobacter pylori infection [3–10], col-
orectal carcinoma and inﬂammatory bowel disease [11],
pancreatic carcinoma and chronic pancreatitis [12].
Unresolved inﬂammation generates a microenvironment
that facilitates cellular transformation and the propagation
of invasive disease. Chronic tissue damage triggers a repair
response including the production of growth and survival
factors, proangiogenesis cytokines, and immune regulatory
networks [7, 8].
The release of inﬂammatory cell-derived reactive oxygen
species coupled with stimulated epithelial cell proliferation
creates an elevated risk of mutagenesis. In addition, cross-
talk between neoplastic cells and immune elements through-
out the smoldering inﬂammation perpetuates the trans-
forming environment, which provides the evolving tumor
cells with suﬃcient opportunity to acquire mutations and
epigenetic alterations that are necessary for cell autonomy.
Inﬂammatory circuits can considerably diﬀer in diﬀerent
tumors in terms of cellular and cytokine networks and2 Clinical and Developmental Immunology
moleculardrivers.However,macrophagesareacommonand
fundamentalcomponentofcancerpromotinginﬂammation.
The drivers of macrophage functional orientation include
tumor cells, cancer-associated ﬁbroblasts, B cells, and T cells.
It is not unfrequent that gastric cancer patients with
the same TNM stage pursue diﬀerent clinical courses.
Histopathologic classiﬁcations, including WHO classiﬁca-
tion [13] and molecular classiﬁcations [14], have also been
applied for the prediction of patient survival, but their
prognostic accuracies are controversial [13]. In addition,
many attempts have been made to link molecular events in
cancer cells with patient outcome, but none of these have
been proved to be clinically meaningful. As a consequence,
new prognostic determinants in conjunction with the TNM
stage are required to more reliably and precisely predict
patients’ clinical course.
As the cancer immunosurveillance hypothesis was ﬁrst
proposed, the concept that the immune system can recognise
and eliminate tumor cells has been energetically debated.
Many experimental studies in rodents have shown that the
immune system indeed functions to protect murine hosts
againstdevelopmentofbothchemicallyinducedandsponta-
n e o u st u m o r s[ 15]. Furthermore, in humans, epidemiologic
investigations indicate that immunocompromised patients
have a higher probability to develop cancersof both viral and
nonviral origin, which supports the cancer immunosurveil-
lance concept [15]. In addition, current evidence indicates a
positive correlation between the presence of lymphocytes in
tumor tissue and increased patient survival.
Recent studies have highlighted that several types of
tumor inﬁltrating lymphocytes (TIL) are associated with
a better disease outcome for various human cancers [16–
18], demonstrating that higher numbers of CD3+,C D 8 +,o r
CD45RO+ T cells in tumor tissue are signiﬁcantly correlated
with lower frequencies of lymph node metastasis, disease
recurrence, or longer patient survival. Wang et al. advocated
that the type, density, and location of immune cells in
colorectal cancer have prognostic values that are superior to
and independent of those of the TNM classiﬁcation [16].
However, tumors have developed a number of diﬀerent
strategies to escape immune surveillance, such as the loss
of tumor antigen expression, the expression of Fas ligand
(Fas-L) or CD200 that can induce apoptosis in activated T
cells, the secretion of immunosuppressive cytokines, such
as IL-10 or TGF-β, or the generation of regulatory T cells,
and MHC downregulation or loss [19]. An alteration in
HLA class I expression occurs in many cancers, such as
gastric cancer [20] and potentially plays a role in the clinical
course of the disease by enabling tumor cells to escape T-
cell-mediated immune responses [21]. Recent observations
suggest that the induction of T-cell apoptosis coexisting with
adownregulationofTCR-ζ moleculesmayberesponsiblefor
T-cell dysfunction in patients with gastric cancer [22].
Within TIL population, there are also T regulatory cells
(Tregs), which are able to inhibit the immune response
mediated by CD4+ and CD8+ T cells in preventing allograft
rejection, graft versus host disease, and autoimmune disease
[23, 24].
In cancer individuals, Tregs were found to downregulate
the activity of eﬀector function against tumors, resulting
in T-cell dysfunction in cancer-bearing hosts [25, 26].
High numbers of Tregs were indeed reported in patients
with diﬀerent type of cancer [27–29]s u c ha sg a s t r i ca n d
esophageal cancer [30]. These observations led us to the
hypothesis that tumor-bearing hosts with advanced cancers
have an increased population of Tregs, which might inhibit
the tumor-speciﬁc T-cell response.
The aim of this paper is to highlight the role of diﬀer-
ent T-cell populations involved in gastric cancer immune
response and to evaluate their impact in blocking/promoting
the development of gastric cancer.
2. Protective Role of Cytotoxic T Cells
A large body of evidence indicates that in gastrointestinal
malignancies, endogenous responses may inhibit tumor
growth and perhaps modulate the clinical course of the
disease. Many reports have been obtained on colorectal
carcinoma: the type, density, and intratumoral location of
the lymphocyte inﬁltrate have been shown to be more infor-
mative biomarkers than the TNM or Duke’s classiﬁcation
[16]. In this context, dense inﬁltrates composed of cytotoxic
memory T cells are strongly associated with a reduced risk
of recurrence after surgery and increased overall survival. In
particular, patients with early-stage cancers but an absence
of T-cell inﬁltrates display poor outcomes, whereas subjects
with signiﬁcant tumor burdens but robust T-cell inﬁltrates
showed improved outcomes [23, 31].
Theprognosticroleoftumor-inﬁltratingimmunecellsin
patients with gastric cancer is largely unknown. Only a few
reports have been issued on the association between tumor
inﬁltrating immune cells and the clinical outcome in GC:
Ishigami et al. [32] reported that patients showing a high
level of natural killer cell inﬁltration in tumor tissues have
a better prognosis, and Maehara et al. [33] showed that a
high density of dendritic cell inﬁltration is associated with
the absence of lymph node metastasis. On the other hand,
the group of Fukuda [34] found no signiﬁcant diﬀerence
in survival between patients with marked or slight TIL
inﬁltration. However, they detected TILs by immunostaining
in GC patients, classiﬁed cases into groups with marked or
slight TIL inﬁltration, and did not determine TIL numbers.
T-cell-mediated adaptive immunity is considered to play
a major role in antitumor immunity. In mouse models, it
has been demonstrated that adaptive immunity prevents the
development of tumors and inhibit tumor progression [35].
Accordingly, recent data [36] showed that in GC high
densities of immune cells related to adaptive immunity
(especially cytotoxic T cells and memory T cells) are
associated with favorable survival and indicate that adaptive
immunity plays a role in the prevention of tumor progres-
sion.
TIL density is also correlated with the presence of lymph
node metastasis but not with the depth of tumor invasion.
On the basis of this ﬁnding, the authors suspect that the
prognostic role of TIL is mainly due to decreased metastaticClinical and Developmental Immunology 3
potential and suggest the following possible mechanisms.
First, the expansion of clones with metastatic potential
usually containing larger amounts of aberrantly expressed
proteins, including proteins that contribute to metastasis,
whichmayactastumor-associatedantigens.Asaresult,these
clones are more likely to be destroyed by in situ immune
reactions. Second, a high density of TIL means a healthy
immune system, and therefore, immune reaction occurring
in lymph node may also exert a proper function against
tumor cells that have drained into lymph nodes in patients
with high TIL densities. Third, tumor burden of metastatic
foci in lymph node is less bulky than those of primary foci,
and thus, metastatic foci are more likely to be susceptible to
complete destruction by immune reaction.
Manyexperimentalandclinicalobservationssuggestthat
metastatic growth in mice and humans is more diﬃcult
to control through vaccination and T-cell response, and
new observations indicate that immunity against early and
even preneoplastic lesions is stronger than against advanced
tumors [37–39]. In some cases, enhanced anticancer T-cell
activity may thus prevent metastasis rather than eliminating
established metastatic nodules. Recently, Kim and coll. [40]
evaluated the antitumor activity of ex vivo expanded T cells
against human GC. For this purpose, human peripheral
blood mononuclear cells were cultured with IL-2-containing
medium in anti-CD3 antibody-coated ﬂasks for 5 days,
followed by incubation in IL-2-containing medium for 9
days. The resulting populations were mostly CD3+ Tc e l l s
(97%): 11% CD4+ and 80% CD8+. This heterogeneous cell
population was also called cytokine-induced killer (CIK)
cells. CIK cells strongly produced IFN-γ,m o d e r a t e l yT N F -
α, but not IL-2 and IL-4. At an eﬀector-target cell ratio
of 30:1, CIK cells destroyed 58% of MKN74 human GC
cells. In addition, CIK cells at doses of 3 and 10million
cells per mouse inhibited 58% and 78% of MKN74 tumor
growth in nude mouse xenograft assays, respectively. This
study suggests that CIK cells may be used as an adoptive
immunotherapy for gastric cancer patients.
The adoptive immunotherapy of GC with CIK cells
has been also reported in preclinical and clinical studies
[41]. MHC-I-restricted CTLs from GC patients recognize
tumor-associated antigen and react speciﬁcally against self-
tumor cells [41–43]. One tumor-speciﬁc antigen, MG7-
antigen, showed great potential for predicting early cancer
as well as for inducing immune responses to GC [44, 45].
Using HLA-A-matched allogeneic GC cells to induce tumor-
speciﬁc CTLs appears to be an alternative immunotherapy
option for gastric cancer [38]. Also, CIK cells in combination
with chemotherapy showed beneﬁts for patients who suﬀer
from advanced gastric cancers [46, 47]. The serum levels
of tumor markers were signiﬁcantly decreased, the host
immune function was increased and the short-term curative
eﬀect as well as the quality of life, were improved in patients
treated by chemotherapy plus CIK cells compared to those in
patients treated by chemotherapy alone [48].
Most studies analyzing T-cell response to tumor-associ-
ated antigens (TAAs) have emphasized CD8+ T cells thus far.
However, CD4+ T cells may play a crucial role in both the
induction and activation of TAA-speciﬁc memory CD8+ T
cells toward cytotoxic eﬀector T cells [49, 50].
Recently Amedei et al. [51] analyzed the functional
properties of the T-cell response to diﬀerent antigen peptides
related to GC in patients with gastric adenocarcinoma. A T-
cell response speciﬁc to diﬀerent peptides of GC antigens
tested was documented in 17 out of 20 patients. Most of the
cancer peptide-speciﬁc TILs expressed a T helper 1 (Th1)/T
cytotoxic 1 (Tc1) proﬁle and cytotoxic activity against target
cells. The eﬀector functions of cancer peptide-speciﬁc T cells
obtainedfromtheperipheralbloodofthesamepatientswere
also studied, and the majority of peripheral blood peptide-
speciﬁc T cells also expressed the Th1/Tc1 functional proﬁle.
In conclusion, in most patients with gastric adenocarci-
noma, a speciﬁc type 1 T-cell response to GC antigens was
detectableandwouldhavethepotentialofhampertumorcell
growth.
3. T Regulatory CellsinCancer
The physiological role of Tregs is the protection against the
autoimmune diseases through the direct suppression of T
eﬀector cells reacting against “self,” although they can be
also involved in the control of immune response against
exogenous antigens [52]. Since most antigens expressed by
neoplastic cells are “self”-antigens [53], it is commonly
considered that Tregs are also involved in the suppression
of the immune response against tumors, favoring tumor
escape from immune response [54]. TILs consist of various
antitumor eﬀector and regulatory subsets. T-cell inﬁltration
is associated with good tumor prognosis in many types of
cancers. CD8+ and CD4+ Tl y m p h o c y t e sa r ee ﬀector cells
thought to be associated with a favorable prognosis [55].
While CD8+ T cells are the main eﬀectors of antitumor
immunity, CD4+ T cells induce and maintain CD8 response
[56]. On the other hand, regulatory lymphocytes, a subset
of T cells which inhibit the antitumor immune reaction
have been described to be associated with unfavorable
prognosis [57–62]. Tregs cells are known to attenuate host
antitumor immunity by suppressing T-cell proliferation,
antigen presentation, and cytokine production [24]. As the
tumor progresses and becomes established in the host, the
population of TILs is skewed to favor regulatory T cells over
the helper CD4+ T cells [56].
Studies of regulatory T cells in GC are very few and
have yielded conﬂicting results. Haas et al. [63]r e p o r t e d
that stromal but not intraepithelial regulatory T cells are
associated with a favorable prognosis. Mizukami et al.
[64] reported that the localization pattern but not the
absolute number of regulatory T cells was associated with
theprognosis.Inbreastcancer,ithasbeendemonstratedthat
pathologic complete response to neoadjuvant chemotherapy
of breast carcinoma is associated with the disappearance of
tumor-inﬁltrating Foxp3+ regulatory T cells [65]. It has been
demonstrated that in some kidney tumors Treg frequency is
signiﬁcantly higher in patients with worse prognosis [66].
Conversely, several recent reports highlighted a protective
role of Treg in cancer [67]. In renal cancer, Siddiqui et4 Clinical and Developmental Immunology
al. showed no correlation between tumor-inﬁltrating Treg
frequency and disease progression [67]. The signiﬁcance of
regulatory T cell in GC as a poor prognostic factor has also
been investigated. Perrone et al. [62]a n dS h e ne ta l .[ 68]
reported unfavorable prognosis with increased intratumoral
regulatory T cells.
Two diﬀerent studies [69, 70] conﬁrmed that GC cell
can induce Tregs development via TGF-β1 production;
in particular the level of serum TGF-β1 in GC patients
(15.1 ± 5.5ng/mL) was signiﬁcantly higher than that of
the gender- and age-matched healthy controls (10.3 ±
3.4ng/mL). Furthermore, the higher TGF-β1 level correlated
with the increased population of CD4+Foxp3+ Tregs in
advancedGC.AsigniﬁcanthigherfrequencyofCD4+Foxp3+
Tregs was observed in PBMCs cultured with the supernatant
of MGC than GES-1 (10.6% ± 0.6% versus 8.7% ± 0.7%).
Moreover, using the puriﬁed CD4+CD25− T cells, the
authors conﬁrmed that the increased Tregs were mainly
induced from the conversation of CD4+CD25− naive T cells,
and induced Tregs were functional and able to suppress the
proliferation of eﬀector T cells. Finally, they demonstrated
that GC cells induced the increase in CD4+Foxp3+ Tregs
via TGF-β1 production. Gastric cancer cells upregulated the
production of TGF-β1 and the blockade of TGF-β1 partly
abrogated Tregs phenotype.
The second study [70] investigated the frequency of
Foxp3+ Tregs within CD4+ cells in TILs, regional lymph
nodes, and PBL of GC patients. Furthermore, to elucidate
the mechanisms behind Treg accumulation within tumors,
authors evaluated the relationship between CCL17 or CCL22
expression and the frequency of Foxp3+ Tregs in GC.
CD4+CD25+Foxp3+ T r e g sw e r ec o u n t e db yﬂ o wc y t o m e t r y
and evaluated by immunohistochemistry. Moreover, an in
vitro migration assay using Tregs derived from GC was
performed in the presence of CCL17 or CCL22. As a result,
the frequency of Foxp3+ Tregs in TILs was signiﬁcantly
higher than that in normal gastric mucosa (12.4% ± 7.5%
versus 4.1% ± 5.3%). Importantly, the increase in Tregs in
TILs occurred to the same extent in early and advanced
disease. Furthermore, the frequency of CCL17+ or CCL22+
cells among CD14+ cells within tumors was signiﬁcantly
higher than that of normal gastric mucosa, and there was
a signiﬁcant correlation between the frequency of CCL171+
or CCL22+ cells and Foxp3+ Tregs in TILs. In addition,
the in vitro migration assay indicated that Tregs were
signiﬁcantly induced to migrate by CCL17 or CCL22. In
conclusion, CCL17 and CCL22 within the tumor are related
to the increased population of Foxp3+ Tregs, with such an
observation occurring in early GC.
Since the Tregs may restrain the antitumor activity of
cytotoxic T cells, the balance of eﬀector and suppressor cells
may also prove to be a decisive factor in patient outcome,
and a recent study [30] contains the ﬁrst evidence related to
the prevalence of Tregs in gastric and esophageal cancer. The
authors shown increased populations of CD4+/CD25+cells
in peripheral blood T cells from patients with gastric and
esophageal cancers in comparison with healthy donors.
Moreover,thepopulationofCD4+/CD25+ cellsintheTILsof
GC was higher than that in normal gastric mucosa. Authors
also conﬁrmed that CD4+/CD25+ isolated from patient
peripheral blood had a regulatory function by evaluating
cytokine production and suppressive activity.
Moreover, the population of CD4+/CD25+ cells in the
TILs of GC patients with advanced disease was signiﬁcantly
more extended than that in TILs of patients with early-
stage disease or that in intraepithelial lymphocytes of normal
gastric mucosa. As a functional consequence, CD4+/CD25+
cellsdidnotproduceIFN-γ butlargeamountsofIL-10.Also,
the proliferation of CD4+/CD25− cells was inhibited in the
presence of CD4+/CD25+ cells in a dose-dependent manner,
so conﬁrming that CD4+/CD25+ has an inhibitory activity
corresponding to Tregs.
Similar results were obtained by Shen and coll.
[71], who demonstrated that increased CD4(+)CD25(+)
CD127(low/−) regulatory T cells were also present in the
tumor microenvironment, such as those found in the
ascites ﬂuid, tumor tissue, or adjacent lymph nodes. In
addition, they found that CD4(+)CD25(+)CD127(low/−)
Tregs suppressed eﬀector T-cell proliferation and also
correlated to advanced stage of GC, suggesting that
CD4(+)CD25(+)CD127(low/−) can be used as a selective
biomarker to enrich human Treg cells and also to perform
functional in vitro assays in GC.
4. Th17 in Cancer
A new subset of Th cells, named Th17 cells, producing IL-
17 alone or in combination with IFN-γ, has been identiﬁed
[72]. Th17 cells may also secrete IL-6, IL-22, and TNF-α and
play a critical role in protection against microbial challenges,
particularly extracellular bacteria and fungi [73]. The role
of Th17 cells in tumor immunology can be dichotomous:
Th17 cells indeed seem to play a role both in tumorigenesis
and eradication of an established tumor. Many laboratories
have studied Th17 populations in blood and occasionally
tissuesofpatientswithvariouscancers.Apotentialprotective
eﬀect of Th17 cells has been reported in cancer aﬀecting
mucosal tissues, such as gut, lung, and skin [74, 75]. An
increase in Th17 cells has been detected in peripheral blood,
tumor microenvironment and tumor-draining lymph nodes
ofseveraldiﬀerenthumanandmousetumortypes[76],such
as ovarian cancer [77].
A recent study has shown that the number of Th17
cells increased in the TILs from melanoma, breast, and
colon cancers [78]; Th17 cells were also suggested as a
prognostic marker in hepatocellular carcinoma [79]. In
contrast to data on solid tumors, little is known about
Th17 cells in hematological malignancies. Serum IL-17
levels were recently shown to be elevated in patients with
multiple myeloma, especially in stages II and III of the
disease. Thus, current data conﬁrm a role for IL-17 in
the promotion of angiogenesis and in the progression
of multiple myeloma [80]. Th17 cell frequencies and IL-
17 concentrations were signiﬁcantly higher in peripheral
blood samples from untreated patients with acute myeloid
leukemia than in those from healthy volunteers and were
reduced in the former after chemotherapy [81].Clinical and Developmental Immunology 5
On the other hand, some studies have found that the
number of Th17 cells is decreased in several types of tumor.
The levels of tumor-inﬁltrating Th17 cells and IL-17 in
ascites were reduced in a group of ovarian cancer patients
with more advanced disease and seemed to positively predict
outcome [82]. A low number of Th17 cell is present in
the tumor microenvironment of non-Hodgkin’s lymphoma
because malignant B cells may upregulate Treg cells and
inhibit Th17 cells [83] .T h 1 7c e l l sa r ep r e s e n ti nm u c hl o w e r
numbers in HER2-positive breast cancer patients than in
either healthy controls or HER2-negative patients [84].
One study in prostate cancer demonstrated that Th17
cells inﬁltrating the tumor correlated inversely with the
Gleason score [85]. This implied that Th17 cells mediate
an antitumor eﬀect in the development of prostate cancer.
One group found that IL-17 promoted the tumorigenicity
of human cervical tumors in nude mice but inhibited the
growth of hematopoietic tumors, mastocytoma P815, and
plasmocytoma in immunocompetent mice [86, 87].
It is clear that the Th17 cells have an ambiguous role
in cancers: they can both encourage and inhibit cancer
progression.
It is well established that IL-17 acts as an angiogenic
factor that stimulates the migration and cord formation of
vascular endothelial cells in vitro and elicits vessel formation
in vivo [88, 89].
The mechanism of Th17 cells upregulation in tumor is
not clear. Charles et al. found that TNF-α enhanced tumor
growth via the inﬂammatory cytokine IL-17 in a mouse
model of ovarian cancer and in patients with advanced can-
cer [90]. Su et al. demonstrated that tumor cells and tumor-
derived ﬁbroblasts secrete monocyte chemotactic protein
1(MCP-1) and RANTES that mediate the recruitment of
Th17 cells [78].
More recently, Kuang et al. showed that tumor-activated
monocytes promote expansion of Th17 cells by secreting
a set of key proinﬂammatory cytokines in the peritumoral
stroma of hepatocarcinoma tissues [91]. It is clear that Treg
cells eﬃcientlysuppressedthefunctionofantitumorCD8+ T
cells [92, 93] .Ar e c e n ts t u d yr e p o r t e dt h a tI L - 2r e g u l a t e st h e
balance between tumor Treg and Th17 cells by stimulating
the diﬀerentiation of the former and inhibiting that of the
latter in the tumor microenvironment [76].
ThemechanismofTh17cells’antitumoractivityremains
largely unknown. One recent work has reported antitumor
activity of IL-17 by means of a T-cell-dependent mechanism
[87].
Two studies by Benatar et al. demonstrated that IL-17E, a
cytokine with signiﬁcant homology to IL-17, has antitumor
activity in multiple tumor models, and that eosinophils and
B cells are involved in the antitumor mechanism of action of
IL-17E [94, 95].
Th17 cells may contribute to protective human tumor
immunity by inducing Th1-type chemokines and stimulat-
ing CXCL9 and CXCL10 production to recruit eﬀector cells
to the tumor microenvironment. A recent study has also
demonstrated that almost half of IL-17-producing CD4+ T
cells isolated from hepatocarcinoma tissues simultaneously
produced IFN-γ [91].
An interesting work of the Gaudernack group has
demonstrated that IL-17-secreting T cell clones obtained
from long-term survivors after immunotherapy also secreted
IFN-γ,I L - 4 ,I L - 5 ,a n dI L - 1 3[ 96]. More recently, it was
shown that Th17 cells and IL-17 participate in antitumor
immunity by facilitating dendritic cell recruitment into
tumortissuesandpromotingtheactivationoftumor-speciﬁc
CD8+ T cells [97].
It was even most intriguing that the Th17 frequencies
increased during treatment with trastuzumab in patients
with breast cancer [82] or with metastatic melanoma treated
with the anticytotoxic T lymphocyte-associated antigen 4
(CTLA4) antibody tremelimumab [10].
Alvarez et al. demonstrated that dendritic and tumor
cell fusions transduced with adenovirus encoding CD40L
eradicate B-cell lymphoma and induce a Th17 type response
in a murine lymphoma model [98]. Moreover, Derhovanes-
sian et al. has observed a highly signiﬁcant correlation
between a higher frequency of IL-17-producing T-cells
prevaccination and a shorter time to metastatic progression
after immunotherapy [99]. These data imply the impor-
tant involvement of Th17 cells in the response to cancer
immunotherapy (Table 1).
Zhang et al. [100] preliminairly reported that compared
with healthy volunteers, patients with GC had a higher
proportion of Th17 cells in peripheral blood. The increased
prevalence of Th17 cells was associated with clinical stage
and in advanced disease increased populations of Th17
cells were present also in tumor-draining lymph nodes.
Furthermore, the mRNA expression levels of Th17-related
factors (IL-17 and IL-23p19) in tumor tissues and the
serum concentrations of IL-17 and IL-23 cytokines were
signiﬁcantly increased in patients with advanced GC. The
results indicate that Th17 cells may contribute to GC
pathogenesis.
5. Concluding Remarks
This paper has highlighted the key roles that T-cell popula-
tions play in promotion and/or protection of gastric cancer.
In summary, high densities of cytotoxic T cells and
memoryTcellsareusuallyassociatedwithfavorablesurvival,
indicating the importance of adaptive immunity in the
prevention of gastric cancer [41]; as a matter of fact the
adoptive immunotherapy of GC with T cells has been also
reported in diﬀerent preclinical and clinical studies [41].
MHC-I restricted CTLs from GC patients recognize tumor-
associated antigen and react speciﬁcally against self-tumor
cells [42, 43], such as MG7-antigen, which shows great
potential for predicting early cancer as well as for inducing
immune responses to GC [44, 45].
Diﬀerent studies sometimes reported controversial
results, for example, some study showed that Tregs are
protective, while others that the Tregs, present in TILs or
in peripheral blood of GC patients, are able to suppress
the eﬀector T cells, thus promoting the tumor progression
[30, 68].6 Clinical and Developmental Immunology
Table 1: Th17 cells in cancer.
Type of cancer Organism Role Eﬀect of subject Reference
Pancreatic cancer Mouse Antitumor
Slower tumor growth
and increased
survival
Gnerlich et al.
[101]
Melanoma Mouse Antitumor
Increase in activated
CD8+ Tc e l l sa n d
better antitumor
eﬃcacy
Sharma et al.
[102]
Melanoma Mouse Antitumor
Th17-polarized cells
were better at tumor
eradication than
Th1-polarized cells
Muranski et al.
[103]
Ovarian cancer Mouse Pro-tumor
Lead to myeloid cell
recruitment in the
tumor environment
and accelerated
tumor growth
Charles et al.
[90]
Hepatocellular
carcinoma Mouse Pro-tumor
Decrease of
intratumoral Th17
was associated with
decreased tumor
growth
Kuang et al. [91]
Prostate cancer Human Pro-tumor
Higher pretreatment
Th17 numbers
correlated with faster
disease progression
Derhovanessian
et al. [99]
Ovarian cancer Human Antitumor
Th17 levels
correlated positively
with patients survival
Kryczek et al.
[82]
Prostate cancer Human Antitumor
More highly
diﬀerentiated Th17
in prostate correlated
with slower disease
progression
Sfanos et al. [85]
Lung
adenocarcinoma Human Antitumor
Th17 accumulation
correlated positively
with patient survival
Ye et al. [104]
In addition, although not conclusively, recent data
suggested that Th17 cells might somehow contribute to GC
pathogenesis [96].
On the basis of clinical and experimental evidence, it is
reasonable to conclude that the T immune response in GC
has double faces as Janus, one friend and one foe, and that to
obtain successful immunotherapy might involve a combined
approach, which intensify the eﬀector functions of cytotoxic
T cells and probably reduce the suppressive T cells.
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